Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time
Manufacturing Inspection Delays Could Impact Decision Due 27 March
Executive Summary
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
You may also be interested in...
Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
BMS Revenues Soar, But High-Flying Revlimid Is A Big Driver
The Celgene acquisition gave BMS a new top-selling drug but Revlimid revenue will start to decline as soon as next year and it is likely to take many new products to replace it.